2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 877

Aberrant Expression of BAFF Receptor (BR3) in Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta
Abstract Number: 660

Abnormal Neutrophil Development in Human Systemic Lupus Erythematosus
Abstract Number: 1650

Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy
Abstract Number: 215

Abnormal Videofluoroscopy Swallow Study Finding in Inflammatory Myopathy Patient with Dysphagia As Predictor of Prognosis
Abstract Number: 1248

Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis
Abstract Number: 2067

Access to Technology and Interest in Mobile “app” for Disease Management Among Patients with Systemic Lupus Erythematosus Seeking Care At a Large Referral Center
Abstract Number: 47

Accumulation of CD34+ Hematopoietic Stem Cells in the Initial Inflammatory Human Fracture Hematoma Is Mediated Via Chemokine Receptor Type 3 Ligands
Abstract Number: 55

Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Seen by Rheumatologists
Abstract Number: 926

Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Using a Random Sample of 7500 Patients Seen in Primary Care
Abstract Number: 155

Accuracy of International Classification of Disease Codes for Calcium Pyrophosphate Disease in the Veterans Adminstration Healthcare System
Abstract Number: 2447

Accuracy of Sensewear Mini^TM and Actigraph GT3X^TM Accelerometers for Differentiating Sedentary and Light Physical Activities in a Controlled Laboratory Setting
Abstract Number: 302

Accuracy of Systemic Lupus International Collaborating Clinics Classiffication Criteria Applied to Juvenile Systemic Lupus Erythematosus Patients
Abstract Number: 1813

Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Abstract Number: 1303

Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Abstract Number: 2011

ACR Criteria, Providers’ Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study

« Previous Page
1
…
7
8
9
10
11
…
180
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].